Grand Rapids, Mich., January 15, 2013 – Michigan Accelerator Fund I (MAF-1) has made a $750,000
Series A-1 investment in Swift Biosciences, Inc. This is the seventh company MAF-1 has funded since the
fund’s inception in 2010, and the first investment since the fund closed at $15.1M in August of 2012.
The investment in Swift Biosciences continues MAF-1’s strategic focus to invest in Michigan-based, early
stage, life science technology companies. Located in Ann Arbor, Swift Biosciences is commercializing
genetic testing technology to advance the field of genomics and personalized medicine. To date, Swift
has launched a product suite referred to as myT® Primers, which enable detection of mutated cells
related to melanoma with extreme sensitivity. This opens the door for test specimens to be collected as
blood samples instead of tissue, which may allow for earlier detection. In 2013, Swift will launch a new
line of products focused on genome sequencing.
“We are thrilled to be investing in Swift at an extremely timely juncture, as their technology is forecast
to hit the market right when the need will be the greatest,” said Dale Grogan, Managing Director, MAF-
1. “We look forward to our investment realizing solid returns in two to three years, if not sooner.”
Launched in 2010 with the backing of several Michigan-based individual investors, MAF-1 now joins
Houston-based Mercury Fund as Swift’s only institutional investors. The total invested in Swift to date is
$6.15M. The latest funding will support product development, patent filing and prosecution, and direct
sales and marketing to key laboratory leaders.
David Olson, CEO, Swift Biosciences added, “The inclusion of MAF-1 as a Michigan-based investor is
highly encouraging, and provides us with additional financial runway as we launch new products in
2013. They are a welcome addition to the Swift team.”
The purpose of Michigan Accelerator Fund I is to achieve significant, long-term capital appreciation for
its investors through investments in Michigan based, early stage companies predominantly in the
healthcare and life science technology sectors. Learn more at www.maf-1.com.
About SWIFT BIOSCIENCES
Swift Biosciences is a small, fast-moving company focused on developing innovative, enabling
technologies for genomics and personalized medicine. Swift’s myT Primer technology was developed to
provide both high sensitivity and specificity in mutation detection, making it ideal for cancer research and diagnostic applications. Multiple Next Generation Sequencing products are staged for commercial
launch in 2013. Learn more at www.swiftbiosci.com.
Michigan Accelerator Fund I
140 Monroe Center, Suite 300
Grand Rapids, MI 49503
Chief Commercial Officer
Swift Biosciences, Inc.
58 Parkland Plaza
Ann Arbor, MI 48103